Molecular Biology, Год журнала: 2024, Номер 58(6), С. 1280 - 1292
Опубликована: Дек. 1, 2024
Язык: Английский
Frontiers in Medicine, Год журнала: 2025, Номер 11
Опубликована: Янв. 13, 2025
Gene therapy has long been a cornerstone in the treatment of rare diseases and genetic disorders, offering targeted solutions to conditions once considered untreatable. As field advances, its transformative potential is now expanding into oncology, where personalized therapies address immune-related complexities cancer. This review highlights innovative therapeutic strategies, including gene replacement, silencing, oncolytic virotherapy, CAR-T cell therapy, CRISPR-Cas9 editing, with focus on their application both hematologic malignancies solid tumors. CRISPR-Cas9, revolutionary tool precision medicine, enables precise editing cancer-driving mutations, enhancing immune responses disrupting tumor growth mechanisms. Additionally, emerging approaches target ferroptosis—a regulated, iron-dependent form death—offering new possibilities for selectively inducing death resistant cancers. Despite significant breakthroughs, challenges such as heterogeneity, evasion, immunosuppressive microenvironment (TME) remain. To overcome these barriers, novel like dual-targeting, armored cells, combination checkpoint inhibitors ferroptosis inducers are being explored. rise allogeneic “off-the-shelf” offers scalable more accessible options. The regulatory landscape evolving accommodate advancements, frameworks RMAT (Regenerative Medicine Advanced Therapy) U.S. ATMP (Advanced Therapy Medicinal Products) Europe fast-tracking approval therapies. However, ethical considerations surrounding CRISPR-based editing—such off-target effects, germline ensuring equitable access—remain at forefront, requiring ongoing oversight. Advances non-viral delivery systems, lipid nanoparticles (LNPs) exosomes, improving safety efficacy By integrating innovations addressing concerns, poised revolutionize cancer treatment, providing durable, effective,
Язык: Английский
Процитировано
4
MicrobiologyOpen, Год журнала: 2024, Номер 13(2)
Опубликована: Март 31, 2024
Abstract Microbial products are essential for developing various therapeutic agents, including antibiotics, anticancer drugs, vaccines, and enzymes. Genetic engineering techniques, functional genomics, synthetic biology unlock previously uncharacterized natural products. This review highlights major advances in microbial biotechnology, focusing on gene‐based technologies medical applications.
Язык: Английский
Процитировано
15
Advanced Healthcare Materials, Год журнала: 2024, Номер 13(20)
Опубликована: Апрель 6, 2024
Abstract The development of functional nanoplatforms to improve the chemotherapy outcome and inhibit distal cancer cell metastasis remains an extreme challenge in management. In this work, a human‐derived PC‐3 membrane‐camouflaged chitosan‐polypyrrole nanogel (CH‐PPy NG) platform, which can be loaded with chemotherapeutic drug docetaxel (DTX) RANK siRNA for targeted gene silencing‐mediated inhibition late‐stage prostate mouse model, is reported. prepared NGs size 155.8 nm show good biocompatibility, pH‐responsive release profile, homologous targeting specificity cells, allowing efficient precise drug/gene co‐delivery. Through in‐vivo antitumor treatment xenografted tumor it shown that such CH‐PPy NG‐facilitated co‐delivery system allows effective slow down growth rate, effectively inhibits bone via downregulation RANK/RANKL signaling pathway. created CH‐Ppy may utilized as promising platform enhanced anti‐metastasis cancer.
Язык: Английский
Процитировано
12
Discover Oncology, Год журнала: 2024, Номер 15(1)
Опубликована: Апрель 29, 2024
Abstract The use of cancer immunotherapeutics is currently increasing. Cancer vaccines, as a form immunotherapy, are gaining much attention in the medical community since specific tumor-antigens can activate immune cells to induce an anti-tumor response. However, delivery vaccines presents many issues for research scientists when designing treatments and requires further investigation. Nanoparticles, synthetic liposomes, bacterial vectors, viral particles, mammalian exosomes have delivered vaccines. In contrast, these nanotechnologies produces cytotoxicity, immunogenicity, rapid clearance by mononuclear phagocyte system (MPS). Plant-exosome-like nanovesicles (PELNVs) provide solutions challenges because they innocuous nonimmunogenic delivering nanomedicines. Hence, this review will describe potential PELNVs deliver review, different approaches vaccine be detailed, mechanism oral vaccination described, discuss improved drug systems via administration while also addressing subsequent advancing their usage into clinical setting.
Язык: Английский
Процитировано
7
OBM Genetics, Год журнала: 2024, Номер 08(01), С. 1 - 501
Опубликована: Март 4, 2024
Gene therapy involves either the direct introduction of genetic material (DNA or RNA) into host cell (or organ), known as <em>in vivo</em> gene therapy, re-introduction modified target cells taken out host, <em>ex therapy. Cancer is mainly caused by non-functioning genes required for normal proliferation, and it has emerged leading cause death globally due to absence efficient safe therapies well early diagnostic modalities. Therapeutic trials using have shown that they considerably increase survival rate life expectancy patients with cancer. There are many potential strategies treatment cancer currently being used, including (a) expressing a induce apoptosis tumor sensitivity conventional drug/radiation therapy; (b) inserting wild-type suppressor compensate its loss/deregulation; (c) blocking expression an oncogene antisense (RNA/DNA) approach; (d) enhancing immunogenicity stimulate immune reactivity. can employ different genes, anti-angiogenesis, any suicidal gene, immunotherapeutic siRNA pro-apoptotic oncolytic gene-directed enzyme prodrug. Moreover, advancements in transfer technologies, various kinds new been developed complement used treat modify DNA directly, such zinc finger nucleases (ZFNs), transcription activator-like effector (TALENs), clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9 (CRISPR/Cas9), etc. Even though there lot progress pre-clinical research both better targeting tumor-selective way, still problems need be fixed before humans. These include non-specific expression, low-efficiency delivery, biosafety. This review will highlight therapy's current challenges future opportunities treatment.
Язык: Английский
Процитировано
6
Viruses, Год журнала: 2023, Номер 15(12), С. 2395 - 2395
Опубликована: Дек. 8, 2023
The hepatitis B virus (HBV) continues to cause substantial health and economic burdens, its target of elimination may not be reached in 2030 without further efforts diagnostics, non-pharmaceutical prevention measures, vaccination, treatment. Current therapeutic options chronic HBV, based on interferons and/or nucleos(t)ide analogs, suppress the replication but do eliminate pathogen suffer from several constraints. This paper reviews progress biotechnological approaches functional definitive HBV treatments, including gene-editing tools, i.e., zinc-finger proteins, transcription activator-like effector nucleases, CRISPR/Cas9, as well therapeutics RNA interference. advantages challenges these are also discussed. Although safety efficacy tools therapies yet demonstrated, they show promise for revitalization a much-needed advance field offer viral eradication. Particular hopes related CRISPR/Cas9; however, employing this system enter clinical testing phases. In contrast, number candidates interference, intending confer cure, have already been introduced human studies. However, larger longer trials required assess their safety. Considering that is always superior treatment, it essential pursue global vaccination.
Язык: Английский
Процитировано
12
Frontiers in Nutrition, Год журнала: 2024, Номер 11
Опубликована: Апрель 16, 2024
Breast milk (BM) is a primary biofluid that plays crucial role in infant development and the regulation of immune system. As class rich biomolecules BM, microRNAs (miRNAs) are regarded as active factors contributing to growth development. Surprisingly, these molecules exhibit resilience harsh conditions, providing an opportunity for infants absorb them. In addition, many studies have shown miRNAs breast milk, when absorbed into gastrointestinal system, can act functional regulators effectively regulate gene expression. Understanding absorption pattern BM miRNA may facilitate creation formula with more optimal balance pave way novel drug delivery techniques. this review, we initially present evidence absorption. Subsequently, compile integrate both vivo vitro findings illustrate bioavailability biodistribution post-absorption. evaluate strengths weaknesses previous discuss potential variables discrepancies their outcomes. This literature review indicates be regulatory agents.
Язык: Английский
Процитировано
3
International Journal of Polymeric Materials, Год журнала: 2024, Номер unknown, С. 1 - 19
Опубликована: Июль 30, 2024
PEGylation has emerged as a promising adaptation in the architecture of nanodelivery systems to improve their physicochemical properties, stability, circulation time, passive targeting tumor tissues, and anticancer efficacy. Owing its heterogeneity, metastatic recurrence potential, ability develop chemoresistance, treatment cancer is one serious challenges for oncologists. The nanotechnology-mediated delivery chemotherapeutics revolutionized oncotherapy through controlling release kinetics, prolonging plasma half-life, enabling diffusion into tissues. Despite numerous biopharmaceutical advantages, clinical translation nanomedicines hampered due recognition elimination from body by mononuclear phagocyte system (MPS). This review presents an overview on including principle, types polyethylene glycol (PEG)-linkers attachment chemistries, current challenges, application various cancer. covalent conjugation PEG with drug(s), biologicals, or nanomaterials adsorptive coating surface shown improvements pharmacokinetic profile, cellular internalization, biodistribution, PEGylated drug(s) plausible adaptations tackle these issues have also been thoroughly discussed this review.
Язык: Английский
Процитировано
3
Oncology Reports, Год журнала: 2024, Номер 52(5)
Опубликована: Авг. 23, 2024
Язык: Английский
Процитировано
3
Опубликована: Янв. 1, 2025
Процитировано
0